New triple therapy offers hope for AML patients

This study tests a new combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as the first treatment for adults with newly diagnosed acute myeloid leukemia (AML). About 30 participants will receive this therapy, followed by standard chemotherapy and, for high-risk patients, a stem cell transplant. The goal is to see if this approach is safe and improves remission rates.